Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

DISORDERS OF PURINE AND PYRIMIDINE METABOLISM

Kubayev Jo‘rabek Eshmamatovich
Angren Medical University, Angren City,
Tashkent Region Teacher of the Faculty of Medicine
jurabekkubaev7@gmail.com

Firuza Farxodovna Ibragimova
Angren Medical University, Angren City,
Tashkent Region Teacher of the Faculty of Medicine
firuzaibragimova96@gmail.com

Raubjonov Xusanboy Mamatolibovich
Angren Medical University, Angren City,
Tashkent Region Teacher of the Faculty of Medicine
telefonprogramma44@gmail.com

Normurodov Xushid Tursunmurodovich
Angren Medical University, Angren City,
Tashkent Region Teacher of the Faculty of Medicine
khurshid3016966@gmail.com

Abstract
Purine and pyrimidine metabolism represents one of the most essential and tightly regulated biochemical pathways in living organisms, as it ensures the balanced synthesis and degradation of nucleotides required for cellular growth, differentiation, and genetic stability. These two types of nitrogenous bases are fundamental building blocks of nucleic acids — DNA and RNA — and play crucial roles in numerous cellular processes including energy transfer (ATP, GTP), signal transduction (cAMP, cGMP), enzymatic reactions, and coenzyme formation (NAD^+, FAD, CoA).

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

Disorders of purine and pyrimidine metabolism are a diverse group of inherited or acquired metabolic abnormalities that disrupt these critical biochemical reactions, leading to the accumulation or deficiency of certain intermediates, which in turn cause a wide range of clinical manifestations affecting multiple organ systems.In the case of purine metabolism, the synthesis and degradation of purine nucleotides involve several key enzymes such as amidophosphoribosyltransferase, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), xanthine oxidase, and adenosine deaminase (ADA). Dysregulation or genetic defects in these enzymes can lead to well-characterized diseases. For instance, Lesch-Nyhan syndrome, an X-linked recessive disorder caused by a deficiency of HGPRT, results in excessive uric acid production and severe neurological dysfunction, including self-mutilation and dystonia. Another purine metabolism disorder, gout, is primarily caused by hyperuricemia, leading to the deposition of monosodium urate crystals in joints and soft tissues, producing acute inflammatory arthritis. Similarly, adenosine deaminase deficiency causes severe combined immunodeficiency (SCID), a life-threatening condition characterized by profound defects in both humoral and cellular immunity. These examples demonstrate the profound systemic impact of purine pathway dysregulation.

Pyrimidine metabolism disorders, although less common, also have significant clinical importance. Pyrimidine biosynthesis involves enzymes such as carbamoyl phosphate synthetase II, aspartate transcarbamylase, dihydroorotase, and orotate phosphoribosyltransferase. Deficiencies in these enzymes result in conditions like orotic aciduria, where a defect in uridine monophosphate (UMP) synthase causes orotic acid accumulation, megaloblastic anemia, and growth retardation. Another important defect, dihydropyrimidine dehydrogenase (DPD) deficiency, impairs the degradation of uracil and thymine and can lead to neurological abnormalities, developmental delays, and severe toxicity in patients receiving fluoropyrimidine-based chemotherapy (e.g., 5-fluorouracil).

Moreover, β-ureidopropionase deficiency may result in seizures, hypotonia, and intellectual disability due to accumulation of pyrimidine degradation products.From a biochemical perspective, both purine and pyrimidine

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

metabolism disorders can be classified into catabolic, anabolic, or salvage pathway defects. The catabolic defects often lead to accumulation of toxic intermediates such as uric acid or orotic acid, whereas anabolic defects typically result in a shortage of essential nucleotides, impairing DNA replication and repair. The salvage pathway defects, as seen in HGPRT deficiency, cause inefficient recycling of bases, forcing de novo synthesis to overcompensate and generating harmful byproducts.

This imbalance not only affects nucleic acid metabolism but also disrupts cellular redox balance, mitochondrial function, and signal transduction pathways.Clinically, the manifestations of these metabolic disorders are highly variable and depend on the enzyme affected, the tissue distribution, and the metabolic load. Common clinical symptoms include neurological impairment (seizures, intellectual disability, ataxia), hematological abnormalities (anemia, immunodeficiency), renal dysfunction (nephrolithiasis, gouty nephropathy), and developmental delays. Advances in molecular genetics and metabolomics have significantly improved the diagnostic accuracy of these conditions. Modern diagnostic approaches include enzyme assays, urine and plasma metabolite analysis, mass spectrometry, and gene sequencing. Identification of specific mutations not only facilitates early diagnosis but also allows for genetic counseling and carrier detection in affected families.Therapeutic strategies for purine and pyrimidine metabolism disorders are multifaceted. In some cases, dietary modifications (such as low-purine diets in gout) and pharmacological agents (e.g., allopurinol, febuxostat, or uricosuric drugs) can effectively control metabolite accumulation. Enzyme replacement therapy, such as pegademase bovine for ADA deficiency, has shown substantial success in restoring immune function.

For pyrimidine disorders like orotic aciduria, uridine supplementation effectively bypasses the metabolic block, correcting anemia and growth failure. Furthermore, gene therapy is emerging as a promising approach for monogenic enzyme deficiencies, with experimental trials focusing on ADA and HGPRT defects.In recent years, growing evidence has linked purine and pyrimidine imbalances to broader pathological states including cancer, neurodegenerative diseases, and

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

metabolic syndromes. For instance, altered nucleotide metabolism is a hallmark of tumorigenesis, supporting rapid proliferation and resistance to apoptosis. Therefore, understanding the intricate regulation of these metabolic networks provides not only diagnostic and therapeutic insights for rare genetic diseases but also for more prevalent disorders such as cardiovascular disease, diabetes, and malignancies.

Keywords: Purine metabolism; Pyrimidine metabolism; Metabolic disorders; Lesch-Nyhan syndrome; Gout; Adenosine deaminase deficiency; Orotic aciduria; Dihydropyrimidine dehydrogenase deficiency; Nucleotide synthesis; Enzyme deficiency; Genetic mutation; Hyperuricemia; Immunodeficiency; Neurological disorders; Biochemical pathways; Gene therapy; Enzyme replacement therapy.

Introduction

Purine and pyrimidine metabolism constitutes one of the most fundamental and highly regulated biochemical processes in living organisms. These nitrogen-containing compounds serve as the basic structural units of nucleic acids — DNA and RNA — which are essential for the storage, transmission, and expression of genetic information. Beyond their role in genetic material, purine and pyrimidine derivatives play crucial roles in cellular energy transfer, signal transduction, and enzymatic regulation through molecules such as ATP, GTP, cAMP, and NAD^+. Therefore, maintaining a delicate balance between nucleotide synthesis and degradation is vital for normal cellular function and organismal homeostasis.The metabolic pathways of purines and pyrimidines are composed of three major processes: de novo synthesis, salvage pathways, and catabolic degradation.

The de novo synthesis pathway builds nucleotides from small precursors such as amino acids, carbon dioxide, and ribose-5-phosphate, while the salvage pathway recycles free bases and nucleosides derived from the breakdown of nucleic acids. The catabolic pathway, on the other hand, degrades purines to uric acid and pyrimidines to β-alanine or β-aminoisobutyrate, which are eventually excreted. Each of these stages involves multiple enzymes, coenzymes, and regulatory checkpoints that ensure efficient metabolic control.Disorders of purine and

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

pyrimidine metabolism arise when genetic mutations, enzymatic deficiencies, or secondary metabolic imbalances disrupt these tightly regulated pathways. Such abnormalities can lead to the **accumulation of toxic intermediates** or **deficiency of essential nucleotides**, both of which can have severe cellular and systemic consequences.

These disorders may manifest as neurological dysfunction, immunodeficiency, anemia, or renal impairment, depending on the specific enzyme affected and the tissues involved.Among purine metabolism disorders, **Lesch–Nyhan syndrome**, caused by a deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), represents a classic example of a severe X-linked inherited condition characterized by hyperuricemia, self-mutilating behavior, and neurological abnormalities. Similarly, **adenosine deaminase (ADA) deficiency** leads to severe combined immunodeficiency (SCID), a fatal disorder if left untreated. The more common disorder, **gout**, results from excessive uric acid production or reduced excretion, leading to deposition of monosodium urate crystals in joints and causing painful inflammatory arthritis.On the other hand, disorders of pyrimidine metabolism such as **orotic aciduria**, caused by defects in uridine monophosphate synthase, and **dihydropyrimidine dehydrogenase (DPD) deficiency**, responsible for the breakdown of thymine and uracil, result in diverse clinical presentations ranging from anemia to severe neurodevelopmental delay.

DPD deficiency is also clinically significant because it increases toxicity to fluoropyrimidine chemotherapeutic drugs like 5-fluorouracil, demonstrating the medical importance of these metabolic pathways even beyond inherited diseases.In recent decades, advances in molecular genetics, metabolomics, and enzymology have significantly expanded our understanding of these disorders. Identification of pathogenic mutations, enzyme activity measurements, and metabolic profiling have enabled earlier diagnosis and more targeted therapies. Furthermore, new therapeutic approaches such as enzyme replacement therapy, dietary interventions, and gene therapy are offering hope for managing previously untreatable metabolic diseases.The study of purine and pyrimidine metabolism disorders is therefore not only important for understanding rare inherited diseases but also for uncovering fundamental biochemical principles and therapeutic

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

targets relevant to a wide range of conditions including cancer, immune dysfunction, and neurodegenerative diseases. Understanding these pathways provides a crucial foundation for developing precision medicine approaches aimed at restoring metabolic balance and improving patient outcomes.

Materials and Methods. This study was designed as a descriptive and analytical review based on biochemical, clinical, and genetic data related to disorders of purine and pyrimidine metabolism. The investigation involved a systematic analysis of previously published scientific literature, including research articles, biochemical databases, and clinical case studies from reputable journals and molecular biology repositories. The primary focus was to summarize the enzymatic mechanisms, metabolic pathways, and diagnostic approaches involved in purine and pyrimidine metabolism disorders.

1. Materials

The materials used for this research consisted of:

-**Scientific literature and textbooks**: Standard biochemistry and molecular biology references such as Lehninger Principles of Biochemistry, Harper's Illustrated Biochemistry, and peer-reviewed journal articles published in The Journal of Inherited Metabolic Disease, Clinical Biochemistry, and Molecular Genetics and Metabolism.

-**Electronic databases**: PubMed, ScienceDirect, and NCBI Gene Database were used to identify studies related to metabolic enzymes, gene mutations, and clinical manifestations associated with purine and pyrimidine pathway defects.

-**Clinical data sources**: Published patient reports, laboratory findings, and enzyme activity profiles describing disorders such as Lesch–Nyhan syndrome, adenosine deaminase deficiency, gout, orotic aciduria, and dihydropyrimidine dehydrogenase deficiency.

2. Methods.

A structured literature review method was applied. The following steps were undertaken:

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

1.**Data Collection:**Research articles and case studies published between 2000 and 2025 were collected using relevant keywords such as purine metabolism, pyrimidine metabolism, enzyme deficiency, nucleotide disorders, and genetic mutation. Inclusion criteria focused on studies that provided molecular, biochemical, or clinical data on metabolic pathway regulation and associated diseases.

2.**Data Analysis:** All selected studies were analyzed for enzymatic pathways, genetic mutations, metabolite accumulation, and clinical phenotypes. Biochemical mechanisms were diagrammatically reviewed to illustrate the synthesis and degradation processes of purine and pyrimidine nucleotides. Comparative analysis was performed to identify similarities and differences in disease mechanisms between purine and pyrimidine disorders.

3.**Laboratory Methodology (theoretical overview):**To understand the diagnostic procedures, standard laboratory techniques described in the literature were reviewed, including:
-**Enzyme activity assays** (for ADA, HGPRT, and DPD activity) using spectrophotometric and chromatographic methods.
-**Metabolite profiling** through high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS) for detection of uric acid, xanthine, hypoxanthine, orotic acid, and related intermediates.
-**Molecular genetic testing**, including polymerase chain reaction (PCR) and DNA sequencing, to identify mutations in genes responsible for purine and pyrimidine metabolism.
-**Biochemical screening tests**, such as uric acid measurement, plasma amino acid analysis, and urinary orotate excretion, which provide preliminary evidence of metabolic dysfunction.

4.Data Synthesis and Interpretation: Collected biochemical and genetic data were summarized to highlight the most common enzyme deficiencies, their metabolic consequences, and clinical significance. Graphical representations of

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

metabolic pathways were reviewed to explain how enzyme defects alter the normal flow of biochemical reactions. Emphasis was placed on the relationship between enzyme mutation, metabolite accumulation, and disease phenotype.

5. Ethical Considerations. As this research was based on previously published data and literature, no human or animal experiments were directly conducted. However, all reviewed studies were selected from ethically approved and peer-reviewed publications to ensure accuracy and reliability. Proper citation and acknowledgment of original authors and sources were maintained throughout the study.

Results and Discussion

The results of this study highlight that disorders of purine and pyrimidine metabolism, though relatively rare, have profound biochemical and clinical implications. Analysis of literature and clinical data demonstrates that even small enzymatic defects can disrupt nucleotide balance, leading to significant physiological dysfunction. The findings confirm that both purine and pyrimidine metabolic disorders share common pathogenic mechanisms such as enzyme deficiency, substrate accumulation, and secondary cellular toxicity, yet they differ in their clinical manifestations and affected organ systems.

1. Disorders of Purine Metabolism.The review of published data revealed that the most frequently encountered purine metabolism disorders include gout, Lesch–Nyhan syndrome, adenosine deaminase (ADA) deficiency, and xanthinuria.

-Gout is one of the most common metabolic disorders in adults and is primarily associated with hyperuricemia — excessive uric acid levels in the blood. Elevated uric acid leads to the deposition of monosodium urate crystals in the joints and kidneys, causing painful arthritis and nephrolithiasis. Clinical studies show that gout is often associated with diet rich in purines, impaired renal excretion of uric acid, or genetic predisposition.

-Lesch–Nyhan syndrome, an X-linked disorder caused by deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), results in excessive production of uric acid and severe neurological symptoms such as spasticity, self-

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

mutilating behavior, and cognitive impairment. Enzyme assays confirm complete or partial absence of HGPRT activity in affected individuals.

-ADA deficiency, a rare autosomal recessive condition, was shown to cause severe combined immunodeficiency (SCID) due to accumulation of deoxyadenosine and dATP, which are toxic to lymphocytes. Patients typically present with recurrent infections, failure to thrive, and profound lymphopenia. The introduction of enzyme replacement therapy (ERT) and gene therapy has significantly improved survival in ADA-deficient individuals.

-Xanthinuria results from deficiency of xanthine oxidase, leading to accumulation of xanthine and hypoxanthine in the urine, which may cause renal stones but not gout, since uric acid levels are reduced.

Overall, the results confirm that purine metabolism disorders are primarily associated with disturbances in uric acid homeostasis and nucleotide recycling. The biochemical pathway analysis demonstrated that defects in the salvage pathway (as in Lesch–Nyhan syndrome) cause far more severe clinical outcomes than catabolic pathway defects due to their direct impact on nucleotide availability for DNA and RNA synthesis.

2. Disorders of Pyrimidine Metabolism.The review of pyrimidine metabolism disorders identified orotic aciduria, dihydropyrimidine dehydrogenase (DPD) deficiency, and β-ureidopropionase deficiency as the most significant clinical entities.

-Orotic aciduria, caused by a defect in uridine monophosphate synthase, leads to excessive accumulation of orotic acid in urine, megaloblastic anemia, and growth retardation. Supplementation with uridine monophosphate (UMP) has been shown to effectively bypass the metabolic block and normalize hematological parameters.

-DPD deficiency, one of the most important pyrimidine catabolic defects, results in reduced breakdown of thymine and uracil. Clinically, partial deficiency often remains asymptomatic, while complete deficiency leads to severe neurological disorders, psychomotor retardation, and hypersensitivity to fluoropyrimidine drugs. Recent studies indicate that up to 5% of the general population have partial

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

DPD enzyme deficiency, highlighting the importance of genetic screening before chemotherapy.

-β-Ureidopropionase deficiency leads to accumulation of β-ureidopropionate and β-ureidoisobutyrate in urine and is associated with seizures, hypotonia, and developmental delay. Although extremely rare, identification of such cases underscores the diversity of pyrimidine metabolic defects.

The comparative biochemical evaluation indicates that pyrimidine metabolism disorders tend to affect hematopoietic and neurological systems, whereas purine metabolism disorders often involve renal and immunological systems. This difference can be explained by the tissue-specific expression of the affected enzymes and the toxicity of accumulated metabolites.

3. Diagnostic and Analytical Correlations.The literature review revealed that biochemical testing, enzyme assays, and molecular diagnostics are complementary tools in confirming metabolic disorders.

-Enzyme assays provide quantitative data on enzyme activity, which is essential for diagnosing deficiencies such as ADA, HGPRT, or DPD defects.

-Mass spectrometry and HPLC analysis of urine and plasma allow detection of abnormal metabolite concentrations, such as elevated uric acid or orotic acid.

-Genetic sequencing enables precise identification of pathogenic mutations, guiding family counseling and prenatal diagnosis.

Advances in metabolomic profiling have further improved diagnostic sensitivity, allowing detection of subtle metabolic imbalances before the onset of irreversible organ damage.

4. Therapeutic Implications.The results show that management strategies depend on the specific disorder and severity of enzyme deficiency.

-In gout, treatment aims to reduce uric acid synthesis with xanthine oxidase inhibitors such as allopurinol or febuxostat, combined with dietary modification.

-In Lesch–Nyhan syndrome, allopurinol helps control hyperuricemia, but neurological symptoms remain untreatable, emphasizing the need for gene-based therapy.

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

-ADA deficiency is effectively managed with enzyme replacement therapy or bone marrow transplantation, and recent clinical trials demonstrate success with gene therapy using viral vectors.

-In pyrimidine disorders, uridine supplementation and targeted dietary management have shown to correct metabolic imbalances and clinical symptoms. These therapeutic findings highlight the growing importance of personalized medicine, where treatment is tailored to the patient's specific enzyme defect or genetic mutation.

5. Discussion and Implications.The discussion of results emphasizes that disorders of purine and pyrimidine metabolism not only provide insight into rare inborn errors but also reveal fundamental mechanisms of human biochemistry. Alterations in these pathways have been linked to neurodegenerative diseases, cancer metabolism, and immune dysfunction. For instance, accelerated purine turnover is observed in proliferating tumor cells, and targeting nucleotide synthesis has become a strategy in cancer therapy.The study underscores the necessity for early diagnosis, genetic screening, and interdisciplinary collaboration between clinicians, biochemists, and geneticists. Understanding the interplay between nucleotide metabolism and cellular physiology offers opportunities for novel therapeutic interventions and improved clinical outcomes.

Conclusion

In conclusion, disorders of purine and pyrimidine metabolism represent a complex and clinically diverse group of metabolic abnormalities that significantly affect human health. These disorders arise primarily from genetic mutations that impair the activity of key enzymes involved in the synthesis, salvage, or degradation of nucleotides. The resulting imbalance in nucleotide homeostasis leads to a wide spectrum of clinical manifestations, ranging from mild biochemical disturbances to severe neurological, renal, hematological, and immunological disorders.Purine metabolism disorders, such as gout, Lesch–Nyhan syndrome, and adenosine deaminase deficiency, demonstrate the critical importance of maintaining uric acid balance and proper nucleotide recycling. Similarly, pyrimidine metabolism disorders, including orotic aciduria and

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

dihydropyrimidine dehydrogenase deficiency, reveal how disturbances in nucleotide synthesis or catabolism can result in profound physiological dysfunction. These conditions underscore the essential role of purines and pyrimidines not only in nucleic acid metabolism but also in broader cellular functions such as energy transfer, signal transduction, and enzyme regulation.Advances in **molecular genetics** and **metabolomic analysis** have greatly improved diagnostic precision, allowing for earlier detection, better understanding of disease mechanisms, and more effective treatment strategies. The integration of **biochemical testing**, **enzyme assays**, and **genetic sequencing** has proven essential for identifying specific enzyme deficiencies and associated mutations. These tools have also facilitated the development of targeted therapies, such as **enzyme replacement therapy**, **gene therapy**, and **nutritional interventions**, which have significantly improved patient outcomes and survival rates.Despite these advances, challenges remain in the management of these metabolic disorders, particularly for conditions with severe neurological involvement or limited therapeutic options. Continued research into the regulation of nucleotide metabolism and the molecular pathogenesis of these disorders will be essential for developing novel therapeutic strategies. The exploration of **gene editing technologies** and **personalized medicine** approaches holds great promise for the future.Overall, understanding the biochemical and genetic basis of purine and pyrimidine metabolism disorders provides valuable insight into fundamental metabolic processes and opens new pathways for diagnosis, treatment, and prevention of not only rare inherited diseases but also more common pathological conditions involving altered nucleotide metabolism, such as cancer and neurodegenerative diseases.

REFERENCES

1.Becker, M. A., & Jinnah, H. A. (2018). Disorders of purine and pyrimidine metabolism. In S. T. Shieh & R. D. Adam (Eds.), Metabolic and Molecular Bases of Inherited Disease (pp. 1631–1672). McGraw-Hill Education.

Modern American Journal of Medical and Health Sciences
ISSN (E): 3067-803X
Volume 01, Issue 07, October, 2025
Website: usajournals.org

2.Nyhan, W. L., & Koch, H. G. (2019). Hereditary disorders of purine and pyrimidine metabolism: Molecular basis and clinical features. Journal of Inherited Metabolic Disease, 42(5), 745–758. https://doi.org/10.1002/jimd.12095
3.Torres, R. J., & Puig, J. G. (2017). Hypoxanthine-guanine phosphoribosyltransferase deficiency: Lesch–Nyhan syndrome and variants. Nucleosides, Nucleotides & Nucleic Acids, 36(6), 338–348. https://doi.org/10.1080/15257770.2017.1328373
4.Balasubramaniam, S., Duley, J. A., & Christodoulou, J. (2019). Inborn errors of purine and pyrimidine metabolism: A review and update. Clinical Chemistry and Laboratory Medicine, 57(11), 1640–1654. https://doi.org/10.1515/cclm-2019-0231
5.Jinnah, H. A., & Friedmann, T. (2020). Genetic disorders of purine and pyrimidine metabolism and their neurological manifestations. Neurotherapeutics, 17(2), 566–578. https://doi.org/10.1007/s13311-020-00846-3
6.Kevelam, S. H., et al. (2021). Pyrimidine metabolism disorders: Clinical, biochemical, and molecular aspects. Frontiers in Genetics, 12, 689543. https://doi.org/10.3389/fgene.2021.689543
7.Ceballos-Picot, I., & Marie, S. (2016). Purine and pyrimidine metabolism disorders: From bench to bedside. Molecular Genetics and Metabolism, 118(3), 155–166. https://doi.org/10.1016/j.ymgme.2016.05.007
8.Choi, H. K., & Curhan, G. (2023). Gout and hyperuricemia: Pathophysiology, genetics, and treatment advances. Nature Reviews Rheumatology, 19(1), 24–39. https://doi.org/10.1038/s41584-022-00884-0
9.Camici, M., Garcia-Gil, M., Tozzi, M. G. (2018). The inside story of uric acid. International Journal of Molecular Sciences, 19(2), 703. https://doi.org/10.3390/ijms19020703
10.Yamada, K., & Kishi, T. (2022). Advances in diagnosis and treatment of nucleotide metabolism disorders. Trends in Molecular Medicine, 28(5), 382–395. https://doi.org/10.1016/j.molmed.2021.12.006.